TaiMed Tests New Eight-Week HIV Treatment
The research-stage dual-antibody therapy aims to simplify HIV care with a recurring bi-monthly infusion schedule.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Should pharmaceutical companies prioritize developing long-acting HIV therapies over maintaining traditional daily oral medication regimens?
TaiMed Biologics is currently testing TMB-365/380, a dual-antibody HIV treatment, in Phase II clinical trials. This research-stage therapy is designed to provide long-acting viral suppression with a dosage frequency of once every eight weeks.
Why it matters
The development of TMB-365/380 aims to address the needs of patients on complex medication regimens by offering a long-acting treatment with a low potential for drug interactions. It represents a potential therapeutic expansion for TaiMed following its 2018 commercialization of the CD4-targeting antibody ibalizumab.
TMB-365/380 utilizes a two-antibody system to neutralize the virus, with one component targeting the CD4 receptor on T cells. The current trial protocol evaluates an infusion schedule every eight weeks.
The players
TaiMed Biologics
A biotechnology firm headquartered in Taiwan that specializes in the development and commercialization of antibody-based treatments for HIV.
The details
TMB-365/380 employs a two-pronged mechanism to manage HIV. The therapy uses one antibody that binds to the CD4 receptor—a protein found on the surface of immune cells that HIV typically targets for entry—and a second antibody that neutralizes the virus directly. By blocking viral entry while simultaneously neutralizing viral particles, the regimen is intended to provide a long-acting therapeutic effect that reduces the need for frequent dosing.
Timeline
2018: TaiMed received regulatory approval for its first HIV therapy, ibalizumab.
2025: Global health data recorded over 41 million people living with HIV.
mid-2027: Expected conclusion date for Phase IIb clinical trials.
2028: Projected timeline for entry into Phase III clinical trials.
The Tech Race
This program builds on the technical foundation established by TaiMed's earlier commercialization of ibalizumab. The move to a dual-antibody approach signifies an effort to improve upon the single-target method of existing therapies.
While TMB-365/380 remains in the clinical trial phase, it is designed to eventually simplify treatment workflows through an eight-week infusion schedule. For current patients, the company's existing therapy, ibalizumab, is available with a maximum out-of-pocket cost of $25 per infusion in the United States.
The takeaway
TaiMed is pursuing a longer-acting therapeutic profile for HIV patients using a dual-targeting approach. Observers should track the conclusion of Phase IIb clinical trials in mid-2027 to see if the drug meets safety and efficacy benchmarks required for Phase III progression.
Further reading
For more on the latest research in therapeutic development, visit the Biotech section.
Source note: This article includes information reported by BioXconomy.
Live Poll
Should pharmaceutical companies prioritize developing long-acting HIV therapies over maintaining traditional daily oral medication regimens?
